Cardiovascular effects of immunosuppression agents
Frontiers in Cardiovascular Medicine, 2022 Immunosuppressive medications are widely used to treat patients with neoplasms, autoimmune conditions and solid organ transplants. Key drug classes, namely calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and purine synthesis ...
Aly Elezaby +4 more
doaj +3 more sources
Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil [PDF]
Anais Brasileiros de Dermatologia, 2014 The main treatment for pemphigus vulgaris are systemic corticosteroids and immunosuppressive agents, but due to adverse reactions and therapeutic failure, new drugs such as rituximab and mycophenolate mofetil have been used.
Stephanie Del Rio Navarrete Biot +5 more
doaj +1 more source
Off-label use of rituximab in dermatology: pemphigus treatment [PDF]
Anais Brasileiros de Dermatologia, 2013 Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis.
Lislaine Bomm +4 more
doaj +1 more source
Infiltrative cardiomyopathies. Report of a case of cardiac sarcoidosis
Iatreia, 2017 Sarcoidosis is characterized by the presence of non-caseating granulomas that may affect any organ. Heart involvement manifests as cardiomyopathy. Frequency of cardiac involvement in sarcoidosis is around 30 %, but only 5 % of such cases are symptomatic.
Muñoz-Ortiz, Édison +3 more
doaj +1 more source
Rituximab: A Magic Bullet for Pemphigus [PDF]
Journal of Clinical and Diagnostic Research, 2017 Introduction: Pemphigus, an autoimmune disease, was fatal before the era of corticosteroids. With the advent of steroids, mortality decreased but morbidity was present due to the side effects of high dose steroids.
V. Anandan +4 more
doaj +1 more source
FK506 IN PEDIATRIC KIDNEY-TRANSPLANTATION - PRIMARY AND RESCUE EXPERIENCE [PDF]
, 1995 Between December 14, 1989, and December 17, 1993,43 patients undergoing kidney transplantation alone at the Children’s Hospital of Pittsburgh received FK506 as the primary immunosuppressive agent. The mean recipient age was 10.2 ± 4.8 years (range 0.7–17.
ELLIS, D +13 more
core +1 more source
Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]
, 2020 On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P. +4 more
core +2 more sources
New immunosuppressive agents in pediatric transplantation
Clinics, 2014 Immunosuppressive therapy in pediatrics continues to evolve. Over the past decade, newer immunosuppressive agents have been introduced into adult and pediatric transplant patients with the goal of improving patient and allograft survival.
Christina Nguyen, Ron Shapiro
doaj +1 more source
Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures [PDF]
, 1993 Our objective was to obtain new information on the in vitro antilymphocytic action of the cytokine synthesis inhibitor FK 506 and the purine biosynthesis inhibitors mycophenolic acid (MPA; the active moiety of RS61443) and mizoribine (MZB) when used ...
A. Zeevi +34 more
core +1 more source
Nonimmunologic targets of immunosuppressive agents in podocytes
Kidney Research and Clinical Practice, 2015 Proteinuria is a characteristic finding in glomerular diseases and is closely associated with renal outcomes. In addition, therapeutic interventions that reduce proteinuria improve renal prognosis.
Tae-Hyun Yoo, Alessia Fornoni
doaj +1 more source